io9 published data in the Journal of Clinical Oncology today demonstrating that its AI biomarker platform OncoGaze identified HRD-positive patients from routine tissue slides

Jul 31, 2024
1 min read

CEO Greg Hamilton describes how patients who were diagnosed with this software platform had better outcomes, how it might increase the treatable patient population, and next steps towards applying for approval as a companion diagnostic for PARP inhibitors.

https://vimeo.com/993159902

Recent Posts

See All

Quell Tx believes that restoring immune balance rather than entirely depleting cells is key for many autoimmune conditions - a phase 1/2 for its CAR-Treg initiated today in RA & Systemic Sclerosis

Protagonist Therapeutics has two medicines in front of FDA right now - we discuss the expertise in peptide based drug development that has enabled them to get to this point

Cambridge, UK based Arecor uses formulation and development expertise to improve the profile of medicines - the company believes it has its own best in class insulin leveraging this

io9 published data in the Journal of Clinical Oncology today demonstrating that its AI biomarker platform OncoGaze identified HRD-positive patients from routine tissue slides

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight